Home/Filings/4/0001209191-23-013844
4//SEC Filing

Lee Gary K. 4

Accession 0001209191-23-013844

CIK 0001806952other

Filed

Feb 27, 7:00 PM ET

Accepted

Feb 28, 6:17 PM ET

Size

6.2 KB

Accession

0001209191-23-013844

Insider Transaction Report

Form 4
Period: 2023-02-24
Lee Gary K.
Chief Scientific Officer
Transactions
  • Award

    Option (right to buy)

    2023-02-24+600,000600,000 total
    Exercise: $2.13Exp: 2033-02-23Common Stock (600,000 underlying)
Holdings
  • Common Stock

    4,702
Footnotes (2)
  • [F1]Shares acquired on November 18, 2022 under the Issuer's 2021 Employee Stock Purchase Plan.
  • [F2]12.5% of the option shares shall vest on August 9, 2023, with the remaining option shares to vest in equal monthly installments over the following forty-two months.

Issuer

Lyell Immunopharma, Inc.

CIK 0001806952

Entity typeother

Related Parties

1
  • filerCIK 0001907345

Filing Metadata

Form type
4
Filed
Feb 27, 7:00 PM ET
Accepted
Feb 28, 6:17 PM ET
Size
6.2 KB